Abstract
Various natural products, such as physostigmine, have long been recognized as inhibitors of the enzyme acetylcholinesterase. Since the recent approval of galanthamine for the treatment of Alzheimers disease by the blockage of acetylcholine degradation, attempts to find other inhibitors of the enzyme have multiplied, leading to promising candidates such as huperzine A. In this review, a listing is presented of natural product inhibitors, both alkaloid and nonalkaloid in origin. These have been isolated from plant, animal and microbial sources. Details of current testing methods on cholinesterases are given, including solution assays and screening techniques by TLC and HPLC.
Keywords: TLC Assays, HPLC Assay, Radiometric Method, AChE activity, Physostigmine, Huperzine A, Amaryllidaceae, Xanthone inhibitors
Current Organic Chemistry
Title: Natural Product Inhibitors of Acetylcholinesterase
Volume: 10 Issue: 8
Author(s): K. Hostettmann, A. Borloz, A. Urbain and A. Marston
Affiliation:
Keywords: TLC Assays, HPLC Assay, Radiometric Method, AChE activity, Physostigmine, Huperzine A, Amaryllidaceae, Xanthone inhibitors
Abstract: Various natural products, such as physostigmine, have long been recognized as inhibitors of the enzyme acetylcholinesterase. Since the recent approval of galanthamine for the treatment of Alzheimers disease by the blockage of acetylcholine degradation, attempts to find other inhibitors of the enzyme have multiplied, leading to promising candidates such as huperzine A. In this review, a listing is presented of natural product inhibitors, both alkaloid and nonalkaloid in origin. These have been isolated from plant, animal and microbial sources. Details of current testing methods on cholinesterases are given, including solution assays and screening techniques by TLC and HPLC.
Export Options
About this article
Cite this article as:
Hostettmann K., Borloz A., Urbain A. and Marston A., Natural Product Inhibitors of Acetylcholinesterase, Current Organic Chemistry 2006; 10 (8) . https://dx.doi.org/10.2174/138527206776894410
DOI https://dx.doi.org/10.2174/138527206776894410 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Flavonoids: Cellular and Molecular Mechanism of Action in Glucose Homeostasis
Mini-Reviews in Medicinal Chemistry Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Apoptosis and Oxidative Stress-Related Diseases: The p66Shc Connection
Current Molecular Medicine A Second Look into the Oxidant Mechanisms in Alzheimers Disease
Current Neurovascular Research Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Neurotensin NTS1-Dopamine D2 Receptor-Receptor Interactions in Putative Receptor Heteromers: Relevance for Parkinson`s Disease and Schizophrenia
Current Protein & Peptide Science Nature and Nurture: Genetic Influences and Gene-Environment Interactions in Depression
Current Psychiatry Reviews Metabolic Syndrome and Its Effect on the Brain: Possible Mechanism
CNS & Neurological Disorders - Drug Targets Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
Current Neuropharmacology miR-7 Replacement Therapy in Parkinson’s Disease
Current Gene Therapy Agar/Chitosan IPN Thin Hydrogel Films with Antimicrobial and Antioxidant Properties for Potential Dressing Applications
Current Applied Polymer Science Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Association of Interleukin-1 and Inteleukin-1 Receptor Antagonist Gene Polymorphisms with Multiple Sclerosis in Azeri Population of Iran
Endocrine, Metabolic & Immune Disorders - Drug Targets Practical Aspects of microRNA Target Prediction
Current Molecular Medicine Cross-Reactivity in Cell-Mediated and IgE-Mediated Hypersensitivity to Glucocorticoids
Current Pharmaceutical Design Central G-Protein Coupled Receptors (GPCR)s as Molecular Targets for the Treatment of Obesity: Assets, Liabilities and Development Status
Current Drug Targets - CNS & Neurological Disorders Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry The Study of HLA Class II and Autoimmune Diabetes
Current Molecular Medicine